Equity Details
Price & Market Data
Price: $1.16
Daily Change: +$0.03 / 2.59%
Daily Range: $1.11 - $1.19
Market Cap: $49,919,704
Daily Volume: 26,894
Performance Metrics
1 Week: -3.82%
1 Month: -35.53%
3 Months: -2.38%
6 Months: -27.12%
1 Year: 17.34%
YTD: -22.80%
About Estrella Immunopharma, Inc. (ESLA)
Find all you need to know about Estrella Immunopharma, Inc. (ESLA)'s market performance. The stock is valued at 1.16, showing a daily change of +$0.03 / 2.59%. Its market capitalization is 49,919,704. Dive into its short-term and long-term performance trends.
Details
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
